Search Results - "HARRISON, Claire"

Current and future status of JAK inhibitors by McLornan, Donal P, Pope, Janet E, Gotlib, Jason, Harrison, Claire N

“…An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease…”
Get full text

Emerging treatments for classical myeloproliferative neoplasms by Vannucchi, Alessandro M., Harrison, Claire N.

“…There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and…”
Get full text

How we manage Philadelphia‐negative myeloproliferative neoplasms in pregnancy by Robinson, Susan E., Harrison, Claire N.

“…Summary The combined incidence of classical Philadelphia‐negative myeloproliferative neoplasm (MPN) is 6–9/100 000 with a peak frequency between 50 and…”
Get full text

Management of myelofibrosis after ruxolitinib failure by Harrison, Claire N, Schaap, Nicolaas, Mesa, Ruben A

“…Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow…”
Get full text

Classification and Personalized Prognosis in Myeloproliferative Neoplasms by Grinfeld, Jacob, Nangalia, Jyoti, Baxter, E. Joanna, Wedge, David C, Angelopoulos, Nicos, Cantrill, Robert, Godfrey, Anna L, Papaemmanuil, Elli, Gundem, Gunes, MacLean, Cathy, Cook, Julia, O’Neil, Laura, O’Meara, Sarah, Teague, Jon W, Butler, Adam P, Massie, Charlie E, Williams, Nicholas, Nice, Francesca L, Andersen, Christen L, Hasselbalch, Hans C, Guglielmelli, Paola, McMullin, Mary F, Vannucchi, Alessandro M, Harrison, Claire N, Gerstung, Moritz, Green, Anthony R, Campbell, Peter J

“…Genetic analysis involving 2035 patients with a myeloproliferative disorder identified eight genomic subgroups with distinct clinical phenotypes, risk of…”
Get full text

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera by Vannucchi, Alessandro M, Kiladjian, Jean Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N, Pane, Fabrizio, Zachee, Pierre, Mesa, Ruben, He, Shui, Jones, Mark M, Garrett, William, Li, Jingjin, Pirron, Ulrich, Habr, Dany, Verstovsek, Srdan

“…Ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was associated with hematocrit control and spleen size reduction in 21% of patients with…”
Get full text

Are we ready for disease modification in myeloproliferative neoplasms? by Harrison, Claire N.

Get full text

Essential thrombocythemia: challenges in clinical practice and future prospects by Godfrey, Anna L., Green, Anna C., Harrison, Claire N.

“…[Display omitted] Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular…”
Get full text

Effect of Mutation Order on Myeloproliferative Neoplasms by Ortmann, Christina A, Kent, David G, Nangalia, Jyoti, Silber, Yvonne, Wedge, David C, Grinfeld, Jacob, Baxter, E. Joanna, Massie, Charles E, Papaemmanuil, Elli, Menon, Suraj, Godfrey, Anna L, Dimitropoulou, Danai, Guglielmelli, Paola, Bellosillo, Beatriz, Besses, Carles, Döhner, Konstanze, Harrison, Claire N, Vassiliou, George S, Vannucchi, Alessandro, Campbell, Peter J, Green, Anthony R

“…About 10% of myeloproliferative neoplasms carry mutations in both TET2 and JAK2 . Clinical presentation, risk of thrombosis, and rates of tumor progression are…”
Get full text

Identifying disease-modifying potential in myelofibrosis clinical trials by Ross, David M., Lane, Steven W., Harrison, Claire N.

“…[Display omitted] The ultimate goal of bringing most new drugs to the clinic in hematologic malignancy is to improve overall survival. However, the use of…”
Get full text

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses by Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N, Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

“…Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated…”
Get full text

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 by McLornan, Donal P, Yakoub-Agha, Ibrahim, Robin, Marie, Chalandon, Yves, Harrison, Claire N, Kroger, Nicolaus

“…Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to…”
Get full text

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review by Ianotto, Jean-Christophe, Curto-Garcia, Natalia, Lauermanova, Marie, Radia, Deepti, Kiladjian, Jean-Jacques, Harrison, Claire N

“…Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our…”
Get full text

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide by Harrison, Claire N., Mead, Adam J., Panchal, Anesh, Fox, Sonia, Yap, Christina, Gbandi, Emmanouela, Houlton, Aimee, Alimam, Samah, Ewing, Joanne, Wood, Marion, Chen, Frederick, Coppell, Jason, Panoskaltsis, Nicki, Knapper, Steven, Ali, Sahra, Hamblin, Angela, Scherber, Robyn, Dueck, Amylou C., Cross, Nicholas C.P., Mesa, Ruben, McMullin, Mary Frances

“…Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage,…”
Get full text

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis by Cervantes, Francisco, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Al-Ali, Haifa Kathrin, Sirulnik, Andres, Stalbovskaya, Viktoriya, McQuitty, Mari, Hunter, Deborah S., Levy, Richard S., Passamonti, Francesco, Barbui, Tiziano, Barosi, Giovanni, Harrison, Claire N., Knoops, Laurent, Gisslinger, Heinz

“…Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions in splenomegaly and marked improvement in disease-related…”
Get full text

Biological drivers of clinical phenotype in myelofibrosis by Mascarenhas, John, Gleitz, Hélène F. E., Chifotides, Helen T., Harrison, Claire N., Verstovsek, Srdan, Vannucchi, Alessandro Maria, Rampal, Raajit K., Kiladjian, Jean-Jacques, Vainchenker, William, Hoffman, Ronald, Schneider, Rebekka K., List, Alan F.

“…Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinical heterogeneity. At the two ends of the disease spectrum…”
Get full text

Anemia in myelofibrosis: Current and emerging treatment options by Passamonti, Francesco, Harrison, Claire N., Mesa, Ruben A., Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Verstovsek, Srdan

“…Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow fibrosis. Clinical manifestations of MF include splenomegaly, constitutional…”
Get full text

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure by Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean‐Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Shen, Juan, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben A.

“…Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk…”
Get full text

A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline by McMullin, Mary Frances, Harrison, Claire N., Ali, Sahra, Cargo, Catherine, Chen, Frederick, Ewing, Joanne, Garg, Mamta, Godfrey, Anna, S, Steven Knapper, McLornan, Donal P., Nangalia, Jyoti, Sekhar, Mallika, Wadelin, Frances, Mead, Adam J.

Get full text

Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives by Harrison, Claire N., Kiladjian, Jean‐Jacques, Koschmieder, Steffen, Passamonti, Francesco

“…The current standard‐of‐care for treatment of myelofibrosis (MF) comprises inhibitors of the Janus kinase (JAK)/signal transducers and activators (STAT)…”
Get full text